CGTX

0.8616

7.04% 0.0567

Dopo l'orario di chiusura: .87 0.0084 +0.97%

Cognition Therapeutics Inc (CGTX)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$0.8049

Aprire:

$0.8

Volume 24 ore:

4.95M

Relative Volume:

0.74

Capitalizzazione di mercato:

$53.41M

Reddito:

Utile/perdita netta:

$-22.83M

Rapporto P/E:

-1.0906

EPS:

-0.79

Flusso di cassa netto:

$-20.87M

1 W Prestazione:

+26.71%

1M Prestazione:

+187.20%

6M Prestazione:

+14.29%

1 anno Prestazione:

-53.17%

Intervallo 1D:

$0.791

$0.8701

Intervallo di 1 settimana:

$0.645

$0.8701

Portata 52W:

$0.2223

$2.535

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Nome

Cognition Therapeutics Inc

Settore

Healthcare (1161)

Industria

Biotechnology (651)

Telefono

412-481-2210

Indirizzo

2403 SIDNEY STREET, PITTSBURGH

Dipendente

Cinguettio

Prossima data di guadagno

2024-08-08

Ultimi documenti SEC

CGTX's Discussions on Twitter

Confronta CGTX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CGTX Cognition Therapeutics Inc	0.8616	48.06M	0	-22.83M	-20.87M	-0.79
VRTX Vertex Pharmaceuticals Inc	472.27	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	564.64	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.74	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.46	31.99B	3.81B	-644.79M	-669.77M	-6.24

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-19	Aggiornamento	B. Riley Securities	Neutral → Buy
2024-07-30	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2021-11-03	Iniziato	B. Riley Securities	Buy
2021-11-03	Iniziato	Oppenheimer	Outperform

Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie

Jul 24, 2025

Cognition Therapeutics Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia

Jul 24, 2025

Jul 23, 2025

What analysts say about Cognition Therapeutics Inc. stockFree Bull & Bear Market Updates - Autocar Professional

Jul 23, 2025

What drives Cognition Therapeutics Inc. stock priceBreakneck growth rates - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is Cognition Therapeutics Inc. a good long term investmentFree Predictions - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire

Jul 21, 2025

Cognition Therapeutics reports positive results for Alzheimer’s drug - Investing.com India

Jul 21, 2025

Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq

Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times

Jul 21, 2025

Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan

Jul 21, 2025

Jul 19, 2025

How high can Cognition Therapeutics Inc. stock price go in 2025Capital Efficient Investment Tips - beatles.ru

Jul 19, 2025

Jul 17, 2025

Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com Nigeria

Jul 16, 2025

CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest

Jul 16, 2025

Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq

Jul 16, 2025

Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire

Jul 16, 2025

Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan

Jul 16, 2025

Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com

Jul 16, 2025

Jul 15, 2025

How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser

Jul 15, 2025

Why Cognition Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser

Jul 15, 2025

What makes Cognition Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser

Jul 15, 2025

Cognition Therapeutics shares fall 1.16% premarket after Karolinska Development's portfolio company Umecrine Cognition raises SEK 24.6 million for clinical development. - AInvest

Jul 15, 2025

Jul 14, 2025

CGTX’s 2025 Market Saga: Unraveling the Story of Gains and Losses - investchronicle.com

Jul 14, 2025

Jul 12, 2025

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 12, 2025

Cognition Therapeutics (NASDAQ:CGTX) Rating Lowered to Strong Sell at Wall Street Zen - Defense World

Jul 12, 2025

Jul 11, 2025

Cognition Therapeutics: Clinical Milestones Ignite Potential in Neurodegenerative Therapeutics - AInvest

Jul 11, 2025